We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

84 hedge funds and large institutions have $171M invested in AVEO Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 6

343% more call options, than puts

Call options by funds: $5.91M | Put options by funds: $1.33M

62% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 13

47% more funds holding

Funds holding: 57 → 84 (+27)

21% less capital invested

Capital invested by funds: $218M → $171M (-$46.7M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
84
Holders Change
+27
Holders Change %
+47.37%
% of All Funds
1.91%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
33
Increased
21
Reduced
13
Closed
6
Calls
$5.91M
Puts
$1.33M
Net Calls
+$4.58M
Net Calls Change
-$519K

Top Buyers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
+$12.3M
2
Citadel Advisors
Citadel Advisors
Florida
+$2.62M
3
EU
Emory University
Georgia
+$1.87M
4
AC
Armistice Capital
New York
+$1.86M
5
Millennium Management
Millennium Management
New York
+$1.83M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$19.5M
2
NLVP
New Leaf Venture Partners
New York
-$4.27M
3
ACA
Avoro Capital Advisors
New York
-$2.48M
4
PA
Perceptive Advisors
New York
-$1.42M
5
EI
EAM Investors
California
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$811K +$616K +19,834 +215%
SIM
27
Spark Investment Management
New York
$748K -$391K -12,580 -32%
EGI
28
EAM Global Investors
California
$683K +$760K +24,477 New
Goldman Sachs
29
Goldman Sachs
New York
$672K +$748K +24,094 New
Northern Trust
30
Northern Trust
Illinois
$575K – – –
EIM
31
Essex Investment Management
Massachusetts
$564K +$160K +5,138 +34%
XSC
32
X-Square Capital
Puerto Rico
$557K +$619K +19,935 New
Victory Capital Management
33
Victory Capital Management
Texas
$464K +$377K +12,135 +269%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$429K +$374K +12,045 +361%
Morgan Stanley
35
Morgan Stanley
New York
$388K +$242K +7,786 +127%
GIM
36
Granahan Investment Management
Massachusetts
$382K +$425K +13,691 New
PCM
37
Prelude Capital Management
New York
$367K +$136K +4,379 +50%
State Street
38
State Street
Massachusetts
$355K +$108K +3,476 +38%
ACP
39
Acuta Capital Partners
California
$347K +$386K +12,434 New
VFA
40
Virtus Fund Advisers
Connecticut
$337K +$375K +12,065 New
CC
41
Cannell & Co
New York
$307K – – –
Wells Fargo
42
Wells Fargo
California
$298K +$331K +10,664 New
BRWA
43
B. Riley Wealth Advisors
Florida
$280K +$310K +10,001 New
Bank of New York Mellon
44
Bank of New York Mellon
New York
$256K +$81.6K +2,628 +40%
GAM
45
Gemmer Asset Management
California
$185K +$23.3K +752 +388%
RCAG
46
Rehmann Capital Advisory Group
Michigan
$148K – – –
VF
47
Virtu Financial
New York
$108K +$120K +3,859 New
TRCT
48
Tower Research Capital (TRC)
New York
$96K +$107K +3,438 New
AIM
49
Alambic Investment Management
California
$95K – – –
Two Sigma Investments
50
Two Sigma Investments
New York
$83K +$92.1K +2,967 New
1
2
3 4

AVEO Hedge Fund Activity: Q4 2017 in Review

84 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2017, worth a combined $171M — down 21% from $218M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new AVEO positions and 6 closed out — a net gain of 27 holders — while 21 added to existing stakes and 13 trimmed.

The largest buyer was Polar Capital, adding an estimated $12.3M. The largest seller was RA Capital Management, cutting an estimated $19.5M.

  • 84 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2017, up from 57 in Q3 2017.
  • Funds reported $171M of AVEO Pharmaceuticals, Inc. stock for Q4 2017, down 21% quarter-over-quarter.
  • 33 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2017 and 6 closed out, a net change of +27 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2017 was Polar Capital, an estimated $12.3M added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q4 2017 was RA Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q4 2017.